Key Points
- CTO Jay Stout sold 1,203 shares on January 7 at an average price of $26.53 for $31,915.59, trimming his stake by 0.60% to 199,611 shares.
- IMVT opened at $26.03 with a market cap of $4.56 billion and a 12‑month range of $12.72–$27.80; the company reported quarterly EPS of ($0.73), missing estimates and reflecting a negative price‑to‑earnings profile.
- Analyst sentiment is mixed but tilted positive with a consensus rating of "Moderate Buy" and a consensus price target of $30.78, while individual price targets range widely (recent notable targets include $28 from Goldman Sachs and $50 from Wolfe Research).
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CTO Jay Stout sold 1,203 shares of the business's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $26.53, for a total transaction of $31,915.59. Following the transaction, the chief technology officer owned 199,611 shares in the company, valued at $5,295,679.83. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Immunovant Trading Down 1.1%
IMVT stock opened at $26.03 on Friday. The company has a market cap of $4.56 billion, a price-to-earnings ratio of -9.17 and a beta of 0.57. Immunovant, Inc. has a 12 month low of $12.72 and a 12 month high of $27.80. The firm has a 50-day moving average of $24.57 and a two-hundred day moving average of $19.49.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.01). During the same period last year, the business posted ($0.74) earnings per share. As a group, equities analysts forecast that Immunovant, Inc. will post -2.69 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have issued reports on IMVT shares. The Goldman Sachs Group upped their target price on Immunovant from $18.00 to $28.00 and gave the company a "neutral" rating in a report on Monday, December 15th. JPMorgan Chase & Co. dropped their price objective on shares of Immunovant from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Tuesday, September 30th. Wolfe Research upgraded shares of Immunovant from a "peer perform" rating to an "outperform" rating and set a $50.00 price objective for the company in a research report on Tuesday. Truist Financial lifted their target price on shares of Immunovant from $16.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunovant in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.78.
Check Out Our Latest Stock Analysis on IMVT
Hedge Funds Weigh In On Immunovant
A number of hedge funds have recently modified their holdings of the business. Strs Ohio acquired a new stake in shares of Immunovant during the 1st quarter worth about $27,000. Aster Capital Management DIFC Ltd purchased a new position in Immunovant during the third quarter worth about $33,000. PNC Financial Services Group Inc. boosted its stake in Immunovant by 138.9% during the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company's stock worth $46,000 after buying an additional 1,646 shares during the period. Farther Finance Advisors LLC increased its position in shares of Immunovant by 142,750.0% during the second quarter. Farther Finance Advisors LLC now owns 2,857 shares of the company's stock valued at $46,000 after acquiring an additional 2,855 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Immunovant by 228.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company's stock valued at $98,000 after acquiring an additional 4,273 shares during the period. 47.08% of the stock is currently owned by hedge funds and other institutional investors.
Immunovant Company Profile
(
Get Free Report)
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
